Incheon Signs Bio and Medical Agreements with Celltrion, Gil Medical Center, and Inha University Hospital

"Incheon Bio Innovation Strategy" Announced at the "2025 Pharmaceutical Bio Investment Expo" on December 2

On December 2, the Incheon Metropolitan Government announced that it had signed two strategic agreements aimed at transforming the city into a "global bio city centered on technological and medical innovation."

On this day, during the "2025 Pharmaceutical Bio Investment Expo" held at Songdo Convensia, the city signed a joint growth agreement for the bio industry with Celltrion.

Under the agreement, Incheon and Celltrion plan to strengthen the technology and research and development (R&D) ecosystem centered around Songdo International City, and, in addition to production and supply chains, will promote ▲research and development, ▲open innovation, and ▲global joint research. This is considered a key industrial strategy to address Incheon's current structure, which is heavily weighted toward production.

The city also signed a medical innovation agreement with Gachon University Gil Medical Center and Inha University Hospital.

These institutions plan to connect the clinical capabilities and medical data assets of research-oriented hospitals in Incheon to the bio industry’s ▲technology validation, ▲clinical collaboration, and ▲medical device commercialization. Through this, the city aims to establish a converged medical-industrial R&D ecosystem in Incheon.

On the 2nd, at Songdo Convensia in Incheon, Ha Byungpil, Deputy Mayor of Incheon, presented the "Incheon Bio Innovation Strategy" at a special session of the "2025 Pharmaceutical Bio Investment Expo." Photo by Yonhap News

Ha Byungpil, Deputy Mayor of Incheon, presented the "Incheon Bio Innovation Strategy" at the "2025 Pharmaceutical Bio Investment Expo" that day, defining Incheon's future model amid the rapidly changing bio industry landscape as a "Bio Growth Partner." He outlined plans to create a full-cycle bio innovation ecosystem centered on Songdo, Yeongjong, and Namdong.

In particular, through the strategy announcement, the city expressed a strong commitment to expanding into a "global bio city centered on technological and medical innovation," leveraging its world-leading production capabilities. The plan is to transition from a production-centered city to one focused on innovation, including AI- and quantum-based drug development and the creation of a venture and talent ecosystem.

Deputy Mayor Ha stated, "These agreements lay the groundwork for Incheon to become a global bio hub," adding, "We will spare no administrative and financial support to create a bio ecosystem that is conducive to business growth."

This content was produced with the assistance of AI translation services.